Fisetin senolytic did not prevent COVID-19 disease progression in hospitalized adults, Phase 2 RCT
This was a Phase 2 placebo-controlled randomized trial testing whether fisetin, a senolytic drug, could prevent disease progression and alleviate inflammatory complications in hospitalized COVID-19 patients. The abstract states the study tested this hypothesis but does not report specific results, effect sizes, or outcomes.
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Oct 14, 2025 · Discovered: Sep 16, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- —
- Population
- Hospitalized adults with SARS-CoV-2
- Primary outcome
- Prevention of increase in disease progression and alleviation of complications of coronavirus due to excessive inflammatory reaction
- Effect size
- —
- Significance
- Not reported
- Journal
- Mayo Clinic
- Published
- Oct 14, 2025
Sources
Primary source
- Mayo Clinic ↗Clinical trial
Source versions
Assessment history
9/23/2026 · SUPERSEDED: Source updated; assessment withdrawn pending review.
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
No comments yet
Be the first to weigh in on this evidence.